| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Balancing act: Tapering mycophenolate mofetil in immune checkpoint inhibitor hepatitis-strategies, outcomes, and risks
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sahaj Mujumdar, Sofia Shaikh, Shu-Yen Chan, Anuroop Yekula, Daniel R Weinberg, Nida S Ansari, David Jerez Diaz, Sarah B McPherson, Mark Levstik, Andrew M Moon and Patrick Twohig |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Patrick Twohig, Assistant Professor, FRCPC, MD, Department of Gastroenterology and Hepatology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14682, United States. patrick_twohig@urmc.rochester.edu |
| Key Words |
Immune checkpoint inhibitor hepatitis; Mycophenolate mofetil; Tapering; immunosuppression; Hepatotoxicity; Immune-related adverse events; Cancer immunotherapy |
| Core Tip |
This systematic review describes immune checkpoint inhibitor hepatitis (ICI) hepatitis and explores the different treatment strategies for this condition, with a focus on the data behind one of the second line agents used for treatment, mycophenolate mofetil (MMF). We review the evidence behind use of MMF for ICI hepatitis, including pathophysiology, clinical outcomes, risk of relapse, tapering strategies, and challenges with restarting immunotherapy in these patients. Future directions and unmet needs within this evolving field are also briefly discussed. |
| Publish Date |
2025-12-05 11:28 |
| Citation |
Mujumdar S, Shaikh S, Chan SY, Yekula A, Weinberg DR, Ansari NS, Jerez Diaz D, McPherson SB, Levstik M, Moon AM, Twohig P. Balancing act: Tapering mycophenolate mofetil in immune checkpoint inhibitor hepatitis-strategies, outcomes, and risks. World J Gastrointest Pharmacol Ther 2025; 16(4): 109485 |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i4/109485.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i4.109485 |
